Globus Medical (GMED)
(Delayed Data from NYSE)
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
Zacks News
Company News for Nov 10, 2022
by Zacks Equity Research
Companies In The News Are: AKAM, AXON, GMED, SRC.
Globus Medical (GMED) Q3 Earnings Lag Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 73.68% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Charles River's (CRL) New Launch to Boost Gene Therapy Workflow
by Zacks Equity Research
Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
Here's Why Investors Should Retain Globus Medical (GMED) For Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.
Globus Medical (GMED) Gains Market Share, Cost Woes Stay
by Zacks Equity Research
Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Globus Medical (GMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 3.70% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Q4 Earnings Match Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Globus Medical (GMED) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.
Globus Medical (GMED) Completes First Cases With Excelsius3D
by Zacks Equity Research
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.
Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.
Globus Medical (GMED) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of -8.70% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.